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A matched nested case–control study of 33 paired cases and controls was conducted, based on
a study cohort in Long An county, Guangxi, China, to determine whether infection with hepatitis B
virus (HBV) with pre-S deletions is independently associated with the development of
hepatocellular carcinoma (HCC), without the confounding effects of basal core promoter (BCP)
double mutations. The prevalence of pre-S deletions was significantly higher in HCC (45.5%, 15
of 33) than the controls (18.2%, 6 of 33) (P,0.01), under the control of the influence of BCP
double mutations. Most of the pre-S deletions occurred in, or involved, the 59 half of the pre-S2
region and the difference between HCC (93.3%, 14 of 15) and controls (66.7%, four of six) was
significant for this region (P50.015). There was no significant difference in pre-S deletions
between the BCP mutant group and BCP wild-type group (P.0.05), nor was the prevalence
of pre-S deletions significantly different between genotypes B and C (P.0.1). These results
suggest that pre-S deletions constitute an independent risk factor for HCC and their emergence
and effect are independent of BCP mutations. The 59 terminus of pre-S2 is the favoured site for
the deletion mutations, especially in HCC cases. Further prospective studies are required to
confirm the role of these mutations in the development of HCC.
INTRODUCTION
Chronic hepatitis B virus (HBV) infection is the most
important aetiology of hepatocellular carcinoma (HCC) in
Asia (Beasley et al., 1981). However, the mechanisms of
oncogenesis are obscure. Recently, viral factors associated
with the development of HCC have become a major focus
for research. The common precore mutation (G1896A) and
mutations in enhancer II (C1653T) and the basal core
promoter (T1753V and the double mutations A1762T and
G1764A) have been reported to be associated with the
development of HCC (Liu et al., 2006; Tanaka et al., 2006;
Chen et al., 2006a; Yuen et al., 2008). Perhaps the most
convincing association is with virus with double mutations
in the basal core promoter (BCP) (Hsia et al., 1996; Fang
et al., 1998, 2002; Baptista et al., 1999; Kao et al., 2003). A
recent prospective study of a cohort of 2258 hepatitis B
surface antigen (HBsAg)-positive individuals in Long An
county, Guangxi, China showed that BCP double muta-
tions are an aetiological factor of HCC (Fang et al., 2008).
Mutations in the BCP may also result in amino acid
substitutions in the X protein and the A1762T, G1764A
mutations result in two, L130M and V131I; however, these
changes decrease the ability of the protein to transactivate
transcription, at least as far as expression of the viral
precore and pregenomic RNAs are concerned (Li et al.,
1999).
HBV can be divided into eight genotypes (designated by
capital letters A to H) based on an intergroup divergence of
8% or more in the complete nucleotide sequence
(Okamoto et al., 1988; Arauz-Ruiz et al., 2002) and these
display remarkable geographical variation. Genotypes B
The GenBank/EMBL/DDBJ accession numbers for the sequences
reported in this study are FM211353–FM211418.
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been reported to have clinical relevance (Kao, 2002).
However, the precise role of these two genotypes in the
development of HCC remains controversial (Chan et al.,
2004; Yu et al., 2005; Sumi et al., 2003; Yuen et al., 2008).
The association between HBV genotype C and HCC may
not be attributable to genotype per se but rather to the high
prevalence of BCP double mutations in patients with
genotype C (Yuen et al., 2004).
The emergence of persistently infected individuals of HBV
with deletions in the pre-S region has been recognized for
many years (Santantonio et al., 1992) and the mutations
have been reported to be more common in genotypes B
and C than in other HBV genotypes (Huy et al., 2003).
Although there is increasing evidence of association of
these mutations with severe liver disease (Tai et al., 2002;
Huy et al., 2003), their clinical significance is rather
obscure, especially their association with HCC. A recent
study from Taiwan reported that the combination of pre-S
deletion mutations and BCP double mutations, rather than
either alone, was associated with the development of HCC
(Chen et al., 2006a). Several subsequent studies also
reported that pre-S deletions are associated with the
development of HCC. However, this association is not
convincing without exclusion of the confounding effect of
BCP double mutations (Choi et al., 2007; Lin et al., 2007;
Gao et al., 2007). The occurrence of pre-S deletions and
BCP mutations is associated with HBV genotype (Sugauchi
et al., 2003) and both are of higher prevalence in genotype
C than in other genotypes (Kao et al., 2003; Sugauchi et al.,
2003). It is possible that the association between pre-S
deletions and HCC may be not attributable to pre-S
deletions per se but rather to the high prevalence of BCP
double mutations in genotype C.
The aim of this study was to determine whether the
association of pre-S deletions with the development of
HCC is independent of BCP double mutations. In this
matched nested case–control study, both cases and controls
were selected from the Long An cohort, Guangxi, China
(Fang et al., 2008).
METHODS
The Long An cohort. In order to determine the value of screening
carriers of HBsAg for virus with core promoter double mutations as a
marker of extremely high risk of developing HCC, a cohort of 2258
hHBsAg-positive subjects, 30–55 years of age, was recruited in
Guangxi, China (Fang et al., 2008). Informed consent in writing
was obtained from each individual. The study protocol conforms to
the ethical guidelines of the 1975 Helsinki Declaration and has been
approved by the Guangxi Institutional Review Board and the UCL
Committee on the Ethics of Non-NHS Human Research (Project
number 0042/001).
Our Chinese study team comprises doctors from Centers for Disease
Prevention and Control (CPDC) of Long An county and the CPDC of
Guangxi Province. From 1 March 2004, the study teams travelled to
128 villages in each of the 12 townships of Long An county to visit
agricultural workers aged 30–55 to collect a 3 ml sample of blood by
venepuncture for screening for HBsAg. All samples were tested for
HBsAg and positive samples were tested in China for HBV DNA by
using nested PCR. We also detected and excluded those samples
positive for anti-hepatitis C virus (HCV) to eliminate the confound-
ing effect of HCV infection on the incidence of HCC. We started to
follow up the study subjects from 1 July 2004. Each study subject
completed a one-page questionnaire at the first visit and provided a
serum sample every six months for the assessment of virological
parameters and alpha fetoprotein (AFP) concentrations and was
monitored for HCC by ultrasonography (US). All cases of HCC
diagnosed were confirmed at the Medical University of Guangxi, the
Cancer Institute of Guangxi or the Hospital of Guangxi (Nanning)
using criteria set by the Chinese Anti-Cancer Association.
HCC cases and controls. After 36 months follow-up, 61 individuals
were diagnosed with HCC and sufficient volumes of serum remained
from 33 (25 males and 8 females, 29 of whom were infected with HBV
with BCP double mutations) for this study. A control was selected
from the cohort for each case, matched for age (where possible,
within 12 months), sex and the status of BCP sequence (wild type or
double mutation) (Table 1).
Serological testing. Sera were tested for HBsAg, HBeAg/anti-HBe,
anti-HCV antibodies and AFP using enzyme immunoassays (Zhong
Shan Biological Technology Company). Alanine aminotransferase
(ALT) levels were determined using a Reitman kit (Sichuan Mike
Scientific Technology Company).
Nested PCR for HBV DNA and nucleotide sequencing. DNA was
extracted from 85 ml serum by Pronase digestion followed by phenol/
chloroform extraction. For nested PCR, first round PCR was carried
out in a 50 ml reaction using primers LSOB1 (nt 2739–2762, 59-
GGCATTATTTGCATACCCTTTGG-39) and MDN5R (nt 1794–1774,
59-ATTTATGCCTACAGCCTCCT-39), or P2 (Gunther et al., 1995),
with 5 min hot start followed by 30 cycles of 94 uC for 30 s, 50 uC for
30 s and 72 uC for 90 s. A second round of PCR was carried out on
5 ml of the first round products in a 50 ml reaction using primers
LSBI1 (nt 2809–2829, 59-TTGTGGGTCACCATATTCTT-39) and
XSEQ1R (nt 1547–1569, 59-CAGATGAGAAGGCACAGACGGGG-39)
and the same amplification protocol as the first round.
Products from the second round were confirmed by agarose gel
electrophoresis and then purified using the GenElute PCR Clean-up
kit (Sigma) according to the manufacturer’s instructions. Cycle
sequencing was carried out directly on both strands using 2 ml
purified amplicon DNA and primer LSBI1 or ADELN (nt 432–453,
59-TAGTCCAGAAGAACCAACAAG-39) and a BigDye Terminator
V3.1 Cycle Sequencing kit (Applied Biosystems) according to the
manufacturer’s instructions. The nucleotide sequences derived in this
study have been submitted to GenBank/EMBL/DDBJ under accession
numbers FM211353–FM211418.
HBV genotyping. HBV genotyping for both cases and controls were
determined using the sequences above and the STAR program [http://
www.vgb.ucl.ac.uk/starn.shtml (Myers et al., 2006)] and the NCBI
Genotyping Tool (http://www.ncbi.nlm.nih.gov/projects/genotyping/
formpage.cgi).
Statistical analysis. The statistical comparisons were performed
using Pearson’s x
2 tests, McNemar’s test and Fisher’s exact test. All P-
values were two-tailed and P,0.05 was considered to be significant.
Univariateandmultivariateconditional logisticregressionanalyseswere
performed using the Statistical Package of Statistical Analysis System
(SAS version 9.0). Variables with P,0.05 on univariate analysis were
analysed by stepwise multivariate analysis for independent risk factors
associated with HCC development. All P-values were two-tailed and
P,0.1 was considered to be significant.
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Rows in bold type denote HCC cases with the matched control immediately below.
Samples Sex Age
(years)
BCP* HBeAg Anti-HBe ALTD Genotype Pre-S2 start
codon
Pre-S deletions*
BC562 F 31 WT ”” 11 C ATG WT
BB224 F 31 WT + 2 5 C ATG WT
BL503 M 52 M ” + 8 B ATG WT
DY008 M 52 M 2 + 7 C ATG WT
BO105 M 53 WT ” + 34 B Deleted 2606–2876,
2998–25
NC073 M 53 WT 2 + 39 C ATA WT
BX72 F 30 M ” + 8 C Deleted 3205–2
CB403 F 30 M 2 + 17 C ATA 3042–3077,
3213–54
CZ662 M 44 M C ATG WT
BL137 M 44 M 2 + 5 C ATG WT
DH230 F 46 WT U/C ATG 2849–2880
DL370 F 46 WT B Deleted 3152–35
DM207 M 36 M ” + 10 B ATG WT
GG311 M 36 M 2 + 7 C ATG WT
GY177 M 35 M ” + 96 C ATC WT
JD90 M 35 M 2 + 37 C ATG WT
JC17 M 42 M C ATA WT
GA130 M 42 M 2 + 140 U/C ATG WT
JO46 F 36 M C ATG 3215–56
JS660 F 36 M 2 + 53 C ATG WT
JS518 M 50 M ” + 73 U/C ATG 3209–47
QP208 M 51 M 2 + 5 B ATG WT
NA102 M 54 M ” + 5 C ATG WT
GM240 M 54 M 2 + 53 B ATG WT
NA407 M 46 M U/C ATG 3215–53
GG091 M 46 M 2 + 7 C ATG WT
DB272 M 48 M ” + 27 B ATG WT
NN079 M 50 M 2 + 55 C ATG WT
ND10 M 39 M C Deleted 3141–51
NS133 M 39 M C Deleted 3151–55
NS052 F 38 M ” + 37 U/C ATG 3215–5
QP244 F 38 M 2 + 10 U/C ATG 2888–3082
PL010 M 37 M ” + 34 C ATG 3215–50
NX083 M 37 M C ATG WT
QB002 M 40 M ” + 84 C ATG WT
NW204 M 40 M 2 + 7 C ATG WT
QD208 M 48 M ” + 5 C GGG WT
QZ034 M 45 M 2 + 90 C ATG WT
QG211 M 41 M ” + 15 C ATA 2981–3083,
3215–5
QF3 M 41 M 2 + 17 C ATG 3004–3183
QL367 M 35 M ”” 37 C ATG WT
PP016 M 35 M 2 + 8 C ATG WT
QP046 M 34 M U/C ATG WT
QG364 M 34 M 2 + 7 C ATG WT
QP257 M 45 M ” + 24 C ATA 3215–51
QS582 M 45 M 2 + 5 C ATG WT
QW026 F 52 M ””5 C ATG WT
BH3 F 53 M ” + 37 C ATG WT
QW037 M 48 M 2 + 31 C ATG 34–54
QQB73 M 48 M ” + 31 C ATG WT
TD019 M 38 M ” + 25 C ATG WT
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The association of pre-S deletions and HCC
Pre-S deletions were found in HBV DNA from 15 of 33
(45.5%) HCC cases tested (Table 2). In contrast, deletions
were found in only six of 33 (18.2%) controls (P,0.01).
There was no significant difference in the prevalence of
deletions between males and females (P.0.1). On uni-
variate analysis, pre-S deletion was independently asso-
ciated with the development of HCC but HBeAg, anti-HBe,
ALT concentrations and genotypes were not. On multi-
variate analysis, pre-S deletion remained independently
associated with the development of HCC (hazard ratio57,
95% confidence limits50.861–56.894) (Table 3). Because
the BCP sequences of matched cases and controls are the
same, the results suggest that the association of pre-S
deletions with the development of HCC is independent of
BCP double mutations.
The locations of the deletions are shown in Fig. 1. All of the
deletions are in-frame so that the integrity of the
polymerase ORF is maintained. Among the 15 HBV
deletion mutations in the HCC group, one (6.7%)
occurred in pre-S1, nine (60%) in the 59 half of the pre-
S2 region and four (26.7%) cases had mutations that
removed the pre-S2 initiation codon and adjacent
sequences. Two of the fifteen had two deletions (one in
pre-S1 and another in the 59 half of the pre-S2 region). In
total, 93.3% of pre-S deletions in this group occurred in or
involved the 59 terminus of the pre-S2 region. In contrast,
of the HBV deletion mutations in the control groups,
33.3% (2/6) occurred in the pre-S1 region, 16.7% (1/6) in
the pre-S2 region and 50% (3/6) had mutations that
removed the pre-S2 initiation codon and adjacent
sequences. In total, 66.7% (4/6) of the pre-S deletions in
the control group occurred in or involved the 59 terminus
of pre-S2. The prevalence of deletions occurring in or
Table 2. Pre-S deletions and HCC
Pre-S deletions between cases and control: McNemar’s test x
257.3636, P,0.01. Pre-S deletions between males and females: Pearson’s x
2 test
x
251.386, P.0.10.
Groups All samples Male samples Female samples
No. Pre-S
deletion
Deletion
rate (%)
No. Pre-S
deletion
Deletion
rate (%)
No. Pre-S
deletion
Deletion
rate (%)
HCC 33 15 45.5 25 11 44.0 8 4 50.0
Control 33 6 18.2 25 3 12.0 8 3 37.5
Total 66 21 31.8 50 14 28.0 16 7 43.8
Table 1. cont.
Samples Sex Age
(years)
BCP* HBeAg Anti-HBe ALTD Genotype Pre-S2 start
codon
Pre-S deletions*
QL523 M 38 M 2 + 34 U/C ATA WT
TX164 M 40 M ” + 44 U/C ATG WT
TZ027 M 40 M ” + 27 C ATG WT
WX116 M 52 M 2 + 18 C ATG WT
BH419 M 52 M ” + 31 C ACG 3215–53
XA282 M 45 M ” + 48 C Deleted 3132–54
XW217 M 45 M 2 + 0 C ATG WT
XD241 M 42 WT ” + 12 U/C ATG 3215–57
XW73 M 42 WT + 2 22 C ATG WT
XW230 F 50 M C ATG WT
YF336 F 50 M ” 2 12 C ATG WT
YJ010 F 47 M 2 + 5 C ATG WT
QF100 F 47 M ” + 3 C ATG WT
YN409 M 55 M ” + 5 C GTA 3215–5
YF003 M 55 M 2 + 35 C ATG WT
*WT, Wild type; M, mutant.
DCut-off ¢40 IU.
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controls (P50.015).
Expression of the middle surface protein also may be
abrogated by point mutations in the pre-S2 initiation
codon. That codon was changed in 18.2% (6/33) of HCC
cases but only 12.1% (4/33) of controls, although the
difference is not statistically significant (P.0.1). The ATG
initiation codon was mutated to ATA in six study subjects
and to ATC, ACG, GGG and GTA (one study subject each)
in the remainder. In addition, six cases with a mixture of
ATG and ATA (one subject), AGG (two subjects) or GTG
(three subjects) were not included in the analysis.
The association of pre-S deletions and BCP
double mutations
Because both pre-S deletions and BCP mutations are more
prevalent in genotype C than other genotypes (Kao et al.,
2003; Sugauchi et al., 2003) it is important to determine
whether the BCP mutations are accompanied by pre-S
deletions or the reverse. When the samples including those
from HCC cases were analysed, no significant difference was
found between the BCP mutant group and wild-type group
in terms of pre-S deletions (x
250.5974, P.0.10; Table 4, top
section). As shown above, pre-S deletions are more prevalent
in the HCC samples and these samples therefore represent a
subset effectively selected for the deletions. For this reason,
the control samples were reanalysed without the HCC cases.
Again, there is no significant difference in the prevalence of
pre-S deletions between the BCP mutant group and wild-
type group (P50.5711; Table 4, bottom section), suggesting
that the emergence of pre-S deletions and BCP mutations are
independent.
The association of pre-S deletions and genotypes
The effect of genotype on the occurrence of pre-S deletions
also was evaluated. In this case–control study, genotypes B
and C were found to infect 10.6% (7/66) and 74.2% (49/
66) of the subjects, respectively. The remainder (15.2%,
10/66) are infected with a recombinant of genotype C and
HBV sequences of unknown genotype (U/C recombinant);
details of this recombinant, described originally in Vietnam
(which neighbours Guangxi), have been presented pre-
viously (Hannoun et al., 2000; Tran et al., 2008). There is
no significant difference in the prevalence of pre-S
deletions among genotypes B and C and the U/C
recombinant, regardless of whether the HCC cases are
included in the analysis (Table 5).
DISCUSSION
This matched nested case–control study reveals that pre-S
deletion is an independent risk factor for HCC and its
emergence and effect are independent of BCP mutations.
The 59 terminus of pre-S2 is the favoured site for the
deletion mutations and the prevalence is significantly
higher in HCC than the controls. The prevalence of pre-S
deletions is not significantly different between genotypes B
and C. The major weakness of this study is that the sample
size (HCC cases) is small, so we cannot carry out
stratification analysis of a synergistic effect with BCP
double mutations in the development of HCC. HBV viral
loads have been reported to be associated with the
development of HCC and 10
4–10
5 copies ml
21 was
suggested to be the cut-off (Chen et al., 2006b, c).
Although we did not measure viral loads for each subject
in this study, the influence of viral loads on the
development of HCC is comparable between cases and
controls; all cases and controls tested positive for HBV
DNA with a nested PCR which spans the discontinuity
between BCP and the 59 end of the minus strand of
genomic DNA and has a detection limit of around 10
3–10
5
genomes ml
21 (Fang et al., 2008). The incidence of HCC in
HBV cirrhotic patients has been found to be greater than in
non-cirrhotic patients (Monto & Wright, 2001). In the
Long An cohort, 67 individuals were known to have
cirrhosis and 39 of the 61 HCC cases occurred in
individuals with cirrhosis (Fang et al., 2008). However,
BCP double mutations, per se, are an independent risk
factor for the development of liver cirrhosis (Fang et al.,
2002; Chen et al., 2005) and cirrhosis was not included in
this analysis. HBV-associated HCC may develop in livers
with minimal histological changes (Brechot et al., 2000);
Table 3. Univariate and multivariate analysis for factors associated with development of HCC
Analysis Variable Parameter
estimate
Standard
error
x
2 Proportion
.x
2
Hazard
ratio
Hazard ratio 95%
confidence limits
Univariate
analysis
HBeAg 217.20289 3846 0.0000 0.9964 0.000 0.000
Anti-HBe 20.69303 1.22472 0.3202 0.5715 0.500 0.045 5.514
ALT 0.22314 0.67082 0.1107 0.7394 1.250 0.336 4.655
Genotype 0.32187 0.47212 0.4648 0.4954 1.380 0.547 3.481
Pre-S 2.30256 1.04880 4.8199 0.0281 10.000 1.280 78.114
Multivariate
analysis
Pre-S 1.94591 1.06904 3.3132 0.0687 7.000 0.861 56.894
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prevalence of HBsAg, such as in Guangxi, where many
adult HBsAg carriers who were infected perinatally may
have life-long persistent infections and remain highly
immune tolerant with minimal hepatitis, but a high risk of
developing HCC. Mutations in enhancer II (C1653T) and
elsewhere in the basal core promoter (T1753V) were found
not to be associated with the development of HCC in our
Fig. 1. Location of deletions detected in HBV
from HCC cases and controls. The upper bar
depicts the wild-type surface ORF; vertical
lines indicate the initiation (pre-S1, pre-S2 and
S) and termination codons (nucleotide posi-
tions are according to standard nomenclature).
The remaining bars represent the surface
ORFs of HBV from 15 HCC cases and six
controls; black rectangles indicate deleted
sequences and the numbers of codons
deleted. The pre-S2 initiation codon is absent
from some isolates.
Table 4. Pre-S deletions and HBV core promoter mutations
Samples including HCC (Pearson’s x
2 test) x
250.5974, P.0.10.
Control samples (McNemar’s test) P50.5711.
Core
promoter
No.
samples
Pre-S
deletion
Deletion
rate (%)
Samples
including
HCC
Mutations
(A1762T,
G1764A)
58 17 29.3
Wild type 8 4 50.0
Samples
without
HCC
Mutations
(A1762T,
G1764A)
29 5 17.2
Wild type 4 1 25.0
Table 5. Pre-S deletions and HBV genotype
Pearson’s x
2 test x
254.3265, P.0.10.
Genotypes All samples
No.
samples
Pre-S
deletion
Deletion rate
(%)
Genotype B 7 2 28.6
Genotype C 49 13 26.5
Genotype U/C 10 6 60.0
Total 66 21 31.8
HBV pre-S deletions and hepatocellular carcinoma
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also were not included in this analysis.
Chen et al. (2006a) reported that a combination of pre-S
deletion mutations and BCP double mutations, rather than
either alone, was associated with the development of HCC
whilst other case–control studies reported that pre-S
deletion is associated with the development of HCC but
did not exclude the confounding effect of BCP double
mutations (Choi et al., 2007; Lin et al., 2007; Gao et al.,
2007). In contrast to the approach using a group case–
control study, the matched nested case–control approach
used in this study decreases the selection and information
bias and increases the comparability. It also proves a causal
association of pre-S deletions and HCC because the
mutations were detected prior to the development of
HCC. Furthermore, our study excludes the confounding
effect of BCP double mutations because both case and
control have the same type of BCP sequence. Therefore,
these results are more reliable than those of previous
studies. Recently, Chen et al. (2007) reported that pre-S
deletions are associated with cirrhosis in HBeAg-negative
patients, independent of BCP double mutations.
As noted above, the polymerase ORF is maintained in all
isolates regardless of the size and number of deletions. All
of the deleted viruses seem to be able to synthesize
truncated versions of the large surface protein, with the
exception of the isolate from HCC case BO105 which has
two extensive deletions and seems unable to make either
the large or middle surface protein, although the major
surface ORF is intact. It is not clear that such a virus is
viable. The sequence from HCC case DH230 is noteworthy;
although it is a U/C recombinant (Hannoun et al., 2000),
the 33 nt deletion at the beginning of the pre-S1 region
resembles that found in genotype D viruses and would
permit synthesis of the large surface protein from the
second, in-frame methionine codon. The remaining
sequences containing deletions, with the exception of two
controls (QP244 and QF3), include deletions (often
starting at or around nt 3215) that remove all or part of
a critical epitope at the beginning of pre-S2. Furthermore,
five sequences with deletions (three HCC cases and two
control), as well as five sequences without deletions (three
HCC cases and two control), have point mutations that
destroy the pre-S2 initiation codon. This epitope, 109–123,
is HLA class I (A3) and class II (DR2) restricted (Barnaba
et al., 1989; Chisari & Ferrari, 1995) and probably the
mutations are selected by immune pressure (Fan et al.,
2001). However, it is not clear why the mutations are
associated with the development of HCC. Hepatocytes
expressing modified large (L) and middle (M) surface
proteins have a potential growth advantage and may be
implicated in the pathogenesis of HBV-related HCC (Fan
et al., 2000). The pre-S2 mutant has been reported to
upregulate cyclin A expression and induce nodular
proliferation of hepatocytes (Wang et al., 2005) and the
modified HBsAg may induce oxidative DNA damage and
mutations in hepatocytes in the late stages of HBV
infection (Hsieh et al., 2004). Furthermore, 39-truncated
pre-S2/S sequences in HBV DNA integrated in HCC have
been proposed to enhance tumour development by
encoding a protein with transcriptional transactivation
activity (Kekule et al., 1990).
Pre-S2 initiation codon mutations may abrogate the
expression of M, resulting in pre-S2-defective variants
(Raimondo et al., 2004). Such variants have been reported
to be associated with advanced liver disease, including
HCC (Choi et al., 2007; Wang et al., 2007). In our study,
the prevalence of such variants in HCC is higher than in
the controls, although the difference is not statistically
significant.
It has been reported that the development of pre-S deletion
mutations is associated with HBV genotype and their
prevalence is higher in genotype C than genotype B in
Taiwan, Japan and mainland China (Chen et al., 2006a;
Sugauchi et al., 2003; Wang et al., 2007). However, an
analysis of samples from 12 countries, including Vietnam,
Nepal, Myanmar, China, Korea, Thailand, Japan, Ghana,
Russia, Spain, USA and Bolivia, showed that the prevalence
of pre-S deletions in genotype C is similar to that in
genotype B (25 versus 24.5%; Huy et al., 2003). In this
study, there is no significant difference between genotypes
B and C in terms of the prevalence of pre-S deletions. The
prevalence of pre-S deletions is higher in the U/C
recombinant than genotypes B and C, although the
difference is not statistically significant. Recombinant
genotypes of HBV have been recognized (Simmonds &
Midgley, 2005; Chen et al., 2006a; Wang et al., 2007;
Schaefer, 2007) but their epidemiology and association
with liver disease need to be investigated further.
In summary, the results of this matched nested case–
control study showed that the pre-S deletion mutations,
particularly deletions involving the pre-S2 region, are
associated with the development of HCC. The pre-S
deletion mutations act independently of BCP mutations.
The development of pre-S deletions and BCP mutations is
independent. There is no significant difference in pre-S
deletions between genotypes B and C but the pre-S
deletions are more common in the U/C recombinant.
However, this is a case–control study and further
prospective studies are needed to confirm the role of these
mutations in the development of HCC.
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